AcelRx pain treatment meets late-stage study goal
(Reuters) - AcelRx Pharmaceuticals Inc said its experimental drug-device combination for post-operative pain met the main goal of a late-stage study on patients who have undergone major open abdominal surgery.
AcelRx shares jumped 10 percent to $5.49 after the bell on Monday.
The top-line results reported from a 178-patient study of AcelRx's sublingual Sufentanil NanoTab PCA system showed that the patient-controlled drug-device combination helped reduce pain significantly compared with a placebo, the company said.
(Reporting by Zeba Siddiqui in Bangalore; Editing by Roshni Menon)
- Target says data from 40 million cards stolen in November-December
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Facebook, Zuckerberg, banks must face IPO lawsuit: judge
- As Modi storms into India's election, a quiet alternative emerges
- Special Report: Why Ukraine spurned the EU and embraced Russia
During Soviet times, Sochi gained a reputation for tolerance but the city's once vibrant gay scene has been shrinking as Russia prepares to host the 2014 Winter Games. Slideshow